TUDOR INVESTMENT CORP ET AL - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 173 filers reported holding DENALI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.

Quarter-by-quarter ownership
TUDOR INVESTMENT CORP ET AL ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$866,873
+67890.0%
42,020
-24.1%
0.01%
-55.0%
Q1 2023$1,275
-8.2%
55,346
+10.8%
0.02%
-25.9%
Q4 2022$1,389
-99.7%
49,931
+203.3%
0.03%
+107.7%
Q2 2022$485,000
-78.3%
16,464
-57.9%
0.01%
-71.1%
Q1 2021$2,233,000
+143.5%
39,106
+3.1%
0.04%0.0%
Q2 2020$917,00037,9260.04%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders